NASDAQ:ABCM

Abcam Competitors

$20.13
-0.18 (-0.89 %)
(As of 04/20/2021 04:30 PM ET)
Add
Compare
Today's Range
$19.96
Now: $20.13
$20.31
50-Day Range
$19.22
MA: $20.42
$22.92
52-Week Range
$17.71
Now: $20.13
$24.69
Volume91,988 shs
Average Volume173,105 shs
Market Capitalization$4.56 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Abcam (NASDAQ:ABCM) Vs. ABCL, SANA, SEER, NUVB, IBRX, and BCAB

Should you be buying ABCM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Abcam, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), and BioAtla (BCAB).

AbCellera Biologics (NASDAQ:ABCL) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for AbCellera Biologics and Abcam, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbCellera Biologics00503.00
Abcam04302.43

AbCellera Biologics currently has a consensus target price of $52.80, suggesting a potential upside of 90.41%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Abcam.

Profitability

This table compares AbCellera Biologics and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbCellera BiologicsN/AN/AN/A
AbcamN/AN/AN/A

Valuation & Earnings

This table compares AbCellera Biologics and Abcam's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera BiologicsN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

AbCellera Biologics beats Abcam on 3 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares Sana Biotechnology and Abcam's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Profitability

This table compares Sana Biotechnology and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
AbcamN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Sana Biotechnology and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Abcam04302.43

Sana Biotechnology presently has a consensus price target of $40.00, suggesting a potential upside of 72.19%. Abcam has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Abcam.

Summary

Sana Biotechnology beats Abcam on 2 of the 3 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Seer (NASDAQ:SEER) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares Abcam and Seer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares Abcam and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
SeerN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Seer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Seer02202.50

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Seer has a consensus price target of $68.00, suggesting a potential upside of 40.76%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Abcam.

Summary

Seer beats Abcam on 2 of the 3 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Profitability

This table compares Abcam and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Nuvation BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Nuvation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Nuvation Bio00603.00

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 73.91%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Abcam.

Valuation & Earnings

This table compares Abcam and Nuvation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Abcam on 3 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares ImmunityBio and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
AbcamN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for ImmunityBio and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Abcam04302.43

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 50.15%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Abcam.

Valuation and Earnings

This table compares ImmunityBio and Abcam's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Abcam on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares BioAtla and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
AbcamN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for BioAtla and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Abcam04302.43

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 23.19%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Abcam.

Valuation and Earnings

This table compares BioAtla and Abcam's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

BioAtla beats Abcam on 3 of the 3 factors compared between the two stocks.


Abcam Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$27.73-6.9%$8.04 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$23.23-2.9%$4.36 billionN/A0.00
SEER
Seer
1.2$48.31-3.5%$2.94 billionN/A0.00Increase in Short Interest
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.01-0.1%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.65-1.9%$1.82 billionN/A0.00Gap Up
BioAtla logo
BCAB
BioAtla
1.5$47.08-1.8%$1.61 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$37.30-5.1%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.3$31.30-2.5%$1.36 billionN/A0.00Analyst Report
News Coverage
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$29.57-0.8%$1.31 billionN/A0.00Analyst Downgrade
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$37.29-1.3%$1.30 billionN/A0.00
EWTX
Cricut
1.1$26.71-0.2%$1.27 billionN/A0.00Analyst Report
News Coverage
Gap Up
KNTE
Kinnate Biopharma
1.7$26.91-2.9%$1.20 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$27.25-4.8%$1.06 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.08-0.9%$982.17 millionN/A0.00Analyst Report
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.93-3.4%$852.34 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$12.90-0.4%$824.08 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.34-3.7%$809.05 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.28-5.7%$782.01 millionN/A0.00
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$23.08-12.7%$734.88 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.23-8.9%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.76-1.6%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.27-0.9%$517.26 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$16.00-0.4%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.84-3.5%$466.11 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.06-7.9%$435.28 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.78-1.9%$429.64 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.46-0.5%$420.11 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$13.30-2.0%$400.10 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.98-1.7%$397.03 millionN/A0.00News Coverage
PRTG
Portage Biotech
0.0$28.15-4.4%$340.14 millionN/A0.00Gap Up
RPHM
Reneo Pharmaceuticals
0.3$12.87-1.2%$311.60 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.91-5.7%$268.57 millionN/A-2.61
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.08-1.5%$258.20 millionN/A-2.40
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.70-1.4%$241.55 millionN/A0.00
VINC
Vincerx Pharma
1.0$16.43-4.8%$229.76 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.22-7.2%$176.28 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$10.14-0.1%$171.54 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.50-3.5%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.34-1.7%$155.20 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.16-4.3%$137.47 millionN/A0.00News Coverage
Gap Up
LGVN
Longeveron
0.3$6.02-3.5%$114.12 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.44-3.2%$74.82 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$30.39-13.5%$71.02 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.37-2.1%$60.07 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.03-3.2%$50.56 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.17-8.1%$43.07 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.77-2.8%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.35-3.3%$36.87 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.06-4.9%$34.28 millionN/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.